Biophysical Determinants Shifting FUS/TDP-43 Phase Separation to Pathological Aggregates

Theorist position for analysis 52661eaf-79f8-4647-8f48-3389f5af4d59: Biophysical Determinants Shifting FUS/TDP-43 Phase Separation to Pathological Aggregates

Source basis: Fundamental Aspects of Phase-Separated Biomolecular Condensates (Chemical Reviews, 2024, DOI 10.1021/acs.chemrev.4c00138). The stored gap context says: Comprehensive review of biomolecular condensate biophysics identified the liquid-to-solid transition in disease-associated RBPs as a major open question requiring in-cell structural approaches.

Primary hypothesis: RNA-binding protein condensate maturation from reversible phase separation to amyloid-like aggregation is not merely an associated signature; it is a testable mechanism that can explain the open question: What are the biophysical determinants — RNA binding stoichiometry, post-translational modifications, crowding agents — that shift FUS and TDP-43 from functional liquid-liquid phase-separated condensates to irreversible amyloid-like aggregates, and can in-cell cryo-electron tomography resolve the structural transitions in patient-derived iPSC motor neurons?

Three candidate claims should be carried forward. First, the strongest causal signal should appear in the cell type or tissue compartment named by the question, not only in bulk disease contrasts. Second, perturbing the axis should shift a proximal molecular phenotype before it shifts a late pathology phenotype, which would help separate cause from consequence. Third, the relevant readout should be stratified by FUS, TDP-43, RNA, because collapsing across those terms would erase the mechanism the analysis is trying to test.

The priority experiment is time-resolved iPSC motor-neuron perturbations combining RNA stoichiometry, PTM mapping, live-cell condensate tracking, and cryo-electron tomography. A positive result would require concordance across human observational data, disease-relevant cellular models, and at least one perturbation that moves the predicted proximal readout in the expected direction.

Skeptic critique for analysis 52661eaf-79f8-4647-8f48-3389f5af4d59: Biophysical Determinants Shifting FUS/TDP-43 Phase Separation to Pathological Aggregates

The source paper motivates the gap, but motivation is not causal evidence. The main threat is that the observed association in Fundamental Aspects of Phase-Separated Biomolecular Condensates could be downstream of disease stage, tissue composition, survival bias, or batch structure. The specific concern here is: in-vitro condensate rules may not transfer cleanly to crowded, stressed patient neurons.

The debate should reject any claim that only restates the title. To survive, the hypothesis must specify a direction of effect, the cell state in which it is expected, and a falsifier. For this analysis, a decisive falsifier would be failure to observe the predicted proximal change after perturbing RNA-binding protein condensate maturation from reversible phase separation to amyloid-like aggregation in the disease-relevant model, even when technical power and cell-state annotation are adequate.

The strongest alternative explanation is that FUS, TDP-43, RNA mark disease severity rather than mechanism. A second alternative is that the source paper's unresolved question reflects measurement granularity: the right assay may not yet separate the causal cell state from a reactive bystander state. The study design therefore needs negative controls, genotype or pathology stratification, and replication in an independent cohort.

Domain expert assessment for analysis 52661eaf-79f8-4647-8f48-3389f5af4d59: Biophysical Determinants Shifting FUS/TDP-43 Phase Separation to Pathological Aggregates

The practical path is feasible but should be staged. Stage 1 should reanalyze or collect human data at the needed resolution, preserving pathology, sex/genotype, region, and disease-stage covariates when relevant. Stage 2 should test RNA-binding protein condensate maturation from reversible phase separation to amyloid-like aggregation in a model where the proximal readout can be measured before overt toxicity. Stage 3 should connect the readout to a translational biomarker or intervention point.

For model systems, prioritize human iPSC-derived disease-relevant cells, co-culture or organoid systems only when the question explicitly requires cross-cell interaction, and mouse models only for organism-level timing or NMJ/vascular phenotypes. Biomarkers should be proximal to mechanism: transcriptional module activity, protein localization, lipid or RNA-modification state, spatial vascular coupling, or motor-unit integrity depending on the gap.

The development risk is moderate. The question is specific enough to generate falsifiable work, and it is anchored to Fundamental Aspects of Phase-Separated Biomolecular Condensates. The risk is that therapeutic tractability may lag mechanistic clarity: even if RNA-binding protein condensate maturation from reversible phase separation to amyloid-like aggregation is causal, the safest intervention point may be an upstream regulator, a cell-state transition, or a biomarker-guided patient subset rather than the named entity itself.